Aspirin Twice Daily in Diabetic Patients With Coronary Artery Disease

Launched by HOPITAL LARIBOISIÈRE · Jun 11, 2012

Keywords

ClinConnect Summary

We have previously demonstrated that there was a time-dependant efficacy of aspirin on platelet function. In this study, we investigate platelet function (fundamental research) according to the delay since last aspirin intake (12 vs 24 hours)in a population of diabetic patients with previous Coronary Artery Disease routinely treated with aspirin. In order to eliminate any variation linked to a cumulative dose effect of aspirn, platelet function is assessed 24 hours after a single 150 mg aspirin intake or 12 hours after a 75 mg aspirin intake given twice per day (corresponding to the same to...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • type 2 diabetes mellitus
• • documented coronary artery disease
• • treatment with aspirin for at least 7 days before randomization
• • one of the following additional criteria defined from our previous study9: current smoking, hs-CRP \> 4mg/L, fibrinogen \> 4g/L and/or platelet count \> 270 103/mm3
• Exclusion Criteria:
• • oral anticoagulants, heparin, thrombolytic agents, non-steroidal anti-inflammatory drugs, prasugrel
• • family or personal history of bleeding or thrombophilic disorders
• • platelet count \> 600x103/mm3 or \< 150x103/mm3
• • hematocrit \> 50% or \< 25%
• • creatinine clearance \< 30mL/min
• • low compliance before enrollment
• • cancer considered not in remission or those having undergone major surgery within the month prior to enrollment.